(Q33897122)

29 July 2017

title

Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? (English)

1 reference

29 July 2017

Wieland E

1

1 reference

29 July 2017

Shipkova M

2

1 reference

29 July 2017

Schellhaas U

3

1 reference

29 July 2017

Schütz E

4

1 reference

29 July 2017

Niedmann PD

5

1 reference

29 July 2017

Armstrong VW

6

1 reference

29 July 2017

Oellerich M

7

1 reference

29 July 2017

publication date

1 March 2000

1 reference

29 July 2017

published in

Clinical Biochemistry

1 reference

29 July 2017

volume

33

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

107-113

1 reference

Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Mycophenolate mofetil for systemic vasculitis and IgA nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Mycophenolate mofetil for severe autoimmune haemolytic anemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Clinical pharmacokinetics of mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

The human UDP glucuronosyltransferase, UGT1A10, glucuronidates mycophenolic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Studies on the reactivity of acyl glucuronides--IV. Covalent binding of diflunisal to tissues of the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Genotoxicity of acyl glucuronide metabolites formed from clofibric acid and gemfibrozil: a novel role for phase-II-mediated bioactivation in the hepatocarcinogenicity of the parent aglycones?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Mycophenolate mofetil-induced colonic ulceration in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Cytokines in intestinal inflammation: pathophysiological and clinical considerations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Enhanced mucosal cytokine production in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Local and systemic liberation of proinflammatory cytokines in ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

IL-1beta and TNF-alpha, but not IFN-alpha, IFN-gamma, IL-6 or IL-8, are secretory mediators in human distal colon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Idebenone protects hepatic microsomes against oxygen radical-mediated damage in organ preservation solutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Mycophenolate mofetil-induced villous atrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Characterization of two UDP glucuronosyltransferases that are predominantly expressed in human colon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Lymphocyte-Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Effect of mycophenolate mofetil (RS-61443) on cytokine production: inhibition of superantigen-induced cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

Differences in the intrinsic capacity of peripheral blood mononuclear cells to produce tumor necrosis factor alpha and beta in patients with inflammatory bowel disease and healthy controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2899%2900101-0

10.1016/S0009-9120(99)00101-0

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference